XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance

Trial Profile

XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Aug 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Ischaemic heart disorders
  • Focus Adverse reactions
  • Acronyms XIENCE Xpedition SV Japan PMS
  • Sponsors Abbott Vascular
  • Most Recent Events

    • 11 Aug 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2021.
    • 06 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top